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Abstract 
Purpose: The purpose of this project was to design and pilot a pharmacist-led process to address medication management across the 
continuum of care within a large integrated health-system. 
Summary: A care transitions pilot took place within a health-system which included a 150-bed community hospital.  The pilot process 
expanded the pharmacist’s medication management responsibilities to include providing discharge medication reconciliation, a 
patient-friendly discharge medication list, discharge medication education, and medication therapy management (MTM) follow-up.  
Adult patients with a predicted diagnosis-related group (DRG) of congestive heart failure or chronic obstructive pulmonary disease 
admitted to the medical-surgical and intensive care units who utilized a primary care provider within the health-system were included 
in the pilot.  Forty patients met the inclusion criteria and thirty-four (85%) received an intervention from an inpatient or MTM 
pharmacist.  Within this group of patients, 88 drug therapy problems (2.6 per patient) were identified and 75% of the drug therapy 
recommendations made by the pharmacist were accepted by the care provider.  The 30-day all-cause readmission rates for the 
intervention and comparison groups were 30.5% and 35.9%, respectively.  The number of patients receiving follow-up care varied 
with 10 (25%) receiving MTM follow-up, 26 (65%) completing a primary care visit after their first hospital discharge, and 23 (58%) 
receiving a home care visit.  
Conclusion: Implementation of a pharmacist-led medication management pilot across the continuum of care resulted in an 
improvement in the quality of care transitions within the health-system through increased identification and resolution of drug 
therapy problems and MTM follow-up.  The lessons learned from the implementation of this pilot will be used to further refine 
pharmacy care transitions programs across the health-system. 
 
 
Introduction 
Healthcare literature is rich with evidence indicating the 
United States has a history of struggling with post-acute care 
transitions that lead to increased hospital readmissions and 
healthcare costs.
1-2
  A significant contributing factor in the 
complexity of these transitions is the presence of medication 
discrepancies or drug therapy problems.  According to Forster 
et al., an adverse event occurs in nearly 20% of patients 
discharged from the hospital to home setting.
3
  Sixty-six 
percent of these adverse events are drug-related, making it 
the most common type of adverse event experienced across 
the continuum of care.  Other studies show the prevalence of 
drug therapy problems in patients being discharged from the 
hospital ranges from 14 - 60%.
4-6
  The literature also shows 
that when pharmacists are involved in care transitions and 
take measures to decrease the prevalence of drug therapy 
problems, the quality of the discharge process is improved 
and rehospitalization rates and preventable adverse drug 
events are lowered.
4-7
    This provides compelling evidence to 
support the need to identify and eliminate gaps in the care 
transitions process, especially drug therapy problems, in 
order to improve care transitions.   
 
While these studies show that incorporating pharmacists into 
the care transitions process has the potential to improve 
medication use and patient outcomes, it is often difficult to 
develop a care transitions program that would meet an 
institution’s and patient population’s specific needs and fit 
within the institution’s operating structure.  Several 
organizations have created guidelines to assist institutions in 
the creation of care transitions programs which aim to 
decrease unnecessary healthcare utilization and improve 
quality of care.
8-11
    Two examples of such programs include 
Project BOOST and Project RED sponsored by the Society of 
Hospital Medicine and the Agency for Healthcare Research 
and Quality, respectively.
8,9
  Each of these projects includes 
medication management as an essential intervention 
component of the discharge process.  While these programs 
provide robust outlines on which types of services should be 
included in the hospital discharge process, they do not 
encompass institution-specific details on how to implement 
sustainable processes or discuss the outpatient interventions 
that are needed to ensure a complete transition. 
 
The objective of this project was to design and pilot a 
pharmacist-led process to address medication management 
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across the continuum of care within Fairview Health Services 
(FHS). 
 
Background 
FHS is a large, integrated health care system in Minnesota 
that has made a commitment to work toward creating an 
accountable care organization. Within this commitment falls 
the need to address the current gaps in care transitions while 
keeping in mind the goals set forth in the Institute for 
Healthcare Improvement’s Triple Aim™.
12
  These goals include 
to improve the health of the population; enhance the patient 
experience of care (including quality, access, and reliability); 
and reduce, or at least control, the per capita cost of care.
12
 
 
In helping FHS move toward accomplishing the Triple Aim™, a 
team consisting of pharmacists, physicians, nurses, and care 
coordinators across the healthcare system was organized 
under an outside project management team to address the 
quality of care transitions post-hospital discharge.  This 
guiding interdisciplinary team decided to pilot a care 
transitions project at Fairview Ridges Hospital, a 150-bed 
community hospital within FHS in Burnsville, MN and 
surrounding Fairview primary care clinics.   
 
As part of the care transitions pilot, Fairview Pharmacy 
Services, the pharmacy service line for FHS, was tasked with 
addressing medication management across the continuum of 
care.  Pharmacists would be responsible for providing 
discharge medication reconciliation, an accurate, patient-
friendly discharge medication list, discharge medication 
education, and MTM follow-up. Historically, at this institution 
inpatient nurses had been responsible for discharge 
medication reconciliation and teaching with pharmacists 
providing consulting services as requested.  MTM services 
were not routinely offered to discharged patients. 
 
Methods 
The care transitions pilot was conducted from October 4, 
2010 – January 28, 2011.  Approval from the University of 
Minnesota Institutional Review Board was obtained.  Adult 
(18 years of age or older), FHS-attributed (i.e., utilizing FHS as 
a primary care provider) patients who were admitted to the 
medical-surgical or intensive care units with a predicted 
diagnosis-related group (DRG) of congestive heart failure 
(CHF) or chronic obstructive pulmonary disease (COPD) were 
included in the pilot.  Non-FHS attributed patients admitted 
to the medical-surgical or intensive care units with a 
predicted DRG of CHF or COPD who received usual care were 
tracked retrospectively as a comparison group.  The 
diagnoses of CHF and COPD were chosen because the 
literature supports an increased risk for readmissions and 
healthcare resource utilization in these patients.
13,14
   
 
Included patients were identified by medical-surgical and 
intensive care unit care coordinators with a nursing 
background and tracked in the care coordination software 
program (Plex Online
a
).  All included patients were followed 
throughout their hospital stay by a decentralized pharmacist 
and their progress was documented on a pharmacy paper 
monitoring form.  Charge nurses, care coordinators, social 
workers, and a discharge liaison pharmacy technician 
attended daily discharge rounds.  The care coordinator and 
discharge liaison pharmacy technician communicated pilot 
inclusion and discharge times to the decentralized pharmacist 
verbally and through the use of Plex Online. 
 
Once discharge orders were written by the inpatient 
provider, the decentralized pharmacist received notification 
in the inpatient electronic health record (Sunrise Clinical 
Manager™ Eclipsys
b
).  The decentralized pharmacist 
reconciled pre-admission medication lists, current admission 
orders, and discharge medication lists.  If any drug therapy 
problems were found, the decentralized pharmacist 
contacted the inpatient provider, discussed any drug therapy 
concerns, and provided drug therapy recommendations.  
Once discharge medication reconciliation was complete, the 
decentralized pharmacist created a discharge medication list 
with patient-friendly language using Assurance System™ 
software
c
 (a documentation system historically used by the 
MTM pharmacists).  The discharge medication list contained 
the medication name, directions, indication, time the next 
dose was due, and a summary of any medication regimens 
had been initiated, discontinued, or modified during the 
patient’s hospital stay. 
 
Using the discharge medication list as a guide, the 
decentralized pharmacist provided medication education to 
the patient, patient’s caregiver, or both.  To guide 
pharmacists in the education process, a script was created 
and used (see Appendix A).  The decentralized pharmacist 
emphasized differences between discharge and pre-
admission medication regimens, answered questions from 
the patient or patient’s caregiver, and provided a copy of the 
discharge medication list to the patient or patient’s caregiver.   
 
Upon completing discharge medication education, the 
decentralized pharmacist used the Assurance System™ to 
document concerns or interventions addressed with the 
inpatient provider, regimens that had been initiated, 
discontinued, or modified during the patient’s hospital stay, 
the patient’s level of understanding, any drug therapy 
problems identified and resolved, and follow-up 
recommendations for the MTM pharmacist.  A note template 
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was created in the Assurance System™ to facilitate this 
documentation process (see Appendix B). 
 
Hospital-based pharmacy services (in-person) and MTM 
services (in-person or via telephone) were offered on 
weekdays during daytime hours only.   All patients were 
offered primary care, home care, and MTM visits upon 
discharge.  The referral for MTM services was made during 
the home care visit.  A process flow map for the care 
transition pilot may be visualized in Figure 1.   
 
Outcome Measures 
The primary outcome measures were the number and 
characterization of drug therapy problems identified by the 
inpatient and MTM pharmacists and the percent of drug 
therapy recommendations accepted by providers in the 
intervention group.  The secondary outcome measures 
included the difference in 30-day all-cause hospital 
readmission rates to any FHS hospital between the 
intervention and comparison groups and the percent of 
intervention patients who received follow-up care. 
 
Results 
During the four month pilot period, 40 patients met the 
inclusion criteria.  The average age was 76 (37-96).  These 
patients had an average of 9 (4-16) medical conditions and 15 
(6-27) medications ordered at discharge.  Table 1 compares 
baseline characteristics of both the intervention and 
comparison groups.  Thirty-four patients (85%) received an 
intervention from an inpatient or MTM pharmacist.  Within 
this group of patients, 88 drug therapy problems (2.6 per 
patient) were identified and 75% of the drug therapy 
recommendations made by the pharmacist were accepted by 
the care provider.  The most common types of drug therapy 
problems identified were needs additional therapy (30%), 
dosage too high (24%), dosage too low (17%), adverse drug 
reaction (13%), unnecessary drug therapy (8%), compliance 
(6%), and different drug needed (3%) [See Figure 2].  Table 2 
provides several illustrative examples of the types of drug 
therapy problems that were identified.  On average, the 
inpatient pharmacist intervention took 92 minutes to 
complete. 
 
The 30-day all-cause readmission rates for the intervention 
and comparison groups were 30.5% and 35.9%, respectively 
(See Figure 3).  The number of patients receiving follow-up 
care varied with 10 (25%) receiving MTM follow-up, 26 (65%) 
receiving a primary care visit after their first hospital 
discharge, and 23 (58%) receiving a home care visit.  
 
Discussion 
Drug therapy problems during care transitions were common 
with an average of 2.6 problems identified per patient seen 
by a pharmacist.  Pharmacists were able to not only 
successfully identify these problems but also resolve them 
75% of the time.  The need for additional therapy was the 
most common drug therapy identified in the pilot.  Often, the 
reason for this drug therapy problem resulted from providers 
inadvertently omitting medications being used to treat a 
chronic medical condition unrelated to the current hospital 
admission (e.g., a prior to admission osteoporosis prevention 
medication for a patient admitted for a CHF exacerbation). 
Other benefits realized during the pilot include increased 
visibility of the pharmacist to patient and increased 
collaboration between interdisciplinary team members.  
Patients seemed generally satisfied with pharmacist-provided 
discharge medication education with one patient who 
remarked that his discharge medication list and education 
were “the best thing since peanut butter.”  In addition to 
increasing pharmacist participation in the discharge process, 
this pilot represented a landmark in pharmacy practice within 
FHS as it required the collaboration of pharmacists between 
various care settings, including inpatient, MTM, and retail, to 
ensure optimal medication management.  
  
 The collective interventions made by the interdisciplinary 
team during the pilot period appeared to show a trend 
toward decreased readmissions with 30-day all-cause 
readmission rates for the intervention and comparison 
groups of 30.5% and 35.9%, respectively.  This decrease in 
resource utilization is consistent with other reports in the 
literature.
4,6,8,9
   
 
Historically, the post-hospital discharge MTM capture rate 
was essentially zero since MTM services were not offered to 
patients. During the pilot, the post-hospital discharge MTM 
capture rate was 25%, allowing for increased pharmacist 
involvement in medication management in the outpatient 
setting.  Although no comparative data was available on 
home care and primary clinic follow-up rates in the 
comparison group, anecdotal reports from staff suggest that 
follow-up rates increased in the intervention group during the 
pilot period.  
 
Limitations 
One of the most significant challenges was the lack of 
dedicated resources.  Additional staffing resources were not 
available for the pilot.  All interdisciplinary team members 
incorporated the additional discharge process tasks into their 
daily workflow which created prioritization challenges and 
resulted in services not being equally provided to all patients 
involved in the pilot.   
 
Since this project was not powered to detect a significant 
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difference between the intervention and comparison groups, 
additional studies with adequate power would be needed to 
draw statistically supported conclusions.  Due to lack of data 
access, rehospitalizations were only tracked for FHS hospitals 
which may have resulted in missed opportunities to capture 
rehospitalizations.  Additionally, it is difficult to compare the 
intervention and comparison groups given the challenges 
associated with categorizing patients based a predicted DRG.  
At the conclusion of the pilot, it was found that while the 
patient may have had a predicted DRG of CHF or COPD, the 
coding process may have resulted in a final unrelated DRG 
being coded.   
 
Several communication challenges arose during the pilot.  
These challenges included conveying process changes 
throughout the project both in and between departments, 
sharing patient discharge dates and times consistently, and 
documenting in multiple electronic health record systems 
(e.g., Plex Online, Sunrise Clinical Manager™ Eclipsys, and 
Assurance™ Systems).  Other logistically driven challenges 
included not having the staffing capacity to provide the 
service on evenings and weekends and developing a new 
referral process that met the requirements of various 
healthcare settings to which the patient was being discharged 
(e.g., home care services, transitional care facilities, and 
primary care clinics). 
 
Future Plans 
Despite the various challenges encountered in this pilot, 
several key learning points were realized and will be used to 
refine and implement future medication management 
programs across the continuum of care.  One change 
currently underway is the implementation of a single 
electronic health record (Epic®
d
) for all inpatient and 
outpatient practice sites.  It is anticipated that the 
implementation of this shared record will eliminate 
duplication of work and decrease the amount of time needed 
to find pertinent patient information.   
 
Another change taking place is the revision of the 
pharmacist’s intervention process.  This involves reviewing 
each step in the discharge process from the patient’s 
admission to follow-up by the MTM pharmacist and 
streamlining work processes in order to increase patient 
capacity for pharmacists.  This also involves refining the MTM 
referral process to ensure consistent communication.   
 
Opportunities for increased staffing capacities are also being 
assessed, including increased pharmacy resident 
involvement. The recent expansion of Fairview Pharmacy 
Services’ residency program will not only provide residents 
with the opportunity to help shape new care transitions 
programs but will also help to allow for more consistent 
staffing of care transitions services. 
 
A group of pharmacists within FHS will also focus on 
developing pharmacy-specific risk stratification criteria based 
on reports in the literature and institution-specific patient 
populations.  These criteria include the number of 
medications, use of high risk medications (e.g., 
hypoglycemics, narcotics, anticoagulants), number of 
modifications in the medication regimen during a hospital 
stay or clinic visit, and hospital admission history.
 4,7-9  
Institution-specific risk stratification calculation programs are 
also being considered. 
 
Conclusion 
Implementation of a pharmacist-led medication management 
pilot across the continuum of care resulted in an 
improvement in the quality of care transitions within FHS 
through increased identification and resolution of drug 
therapy problems and MTM follow-up.  The lessons learned 
from the implementation of this pilot will be used to further 
refine pharmacy care transitions programs across FHS. 
 
Footnotes 
a
Plex Online, Plex Systems, Inc., Auburn Hills, MI 
b
Sunrise Clinical Manager™ Eclipsys (FCIS), Allscripts™, 
Chicago, IL 
c
Assurance System™, Medication Management Systems, Inc., 
Plymouth, MN 
d
Epic®, Epic Systems Corporation, Verona, WI 
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Table 1. Patient Characteristics by Intervention or Comparison Group 
Characteristic 
Intervention 
(n = 40) 
Comparison 
(n = 40) 
Mean patient age in years (range) 
 
76 (37-96) 72 (36-95) 
Number of female patients (% of total patients) 
 
27 (68%) 20 (50%) 
Number of patients with predicted DRG of CHF (% of 
total patients) 
 
24 (60%) 24 (60%) 
Number of patients with predicted DRG of COPD (% of 
total patients) 
 
16 (40%) 16 (40%) 
Mean number of medical conditions per patient 
(range) 
 
9 (4-16) 7 (3-14) 
Mean number of discharge medications per patient 
(range) 
15 (6-27) 14 (3-27) 
                                       CHF = Congestive heart failure, COPD = Chronic obstructive pulmonary disease 
                                       DRG = Diagnosis-related group 
 
 
Table 2. Illustrative Examples of Drug Therapy Problems 
Drug Therapy Problem Description 
Needs additional therapy: 
Preventative therapy 
Patient with CHF and cardiovascular risk factors was started on aspirin while 
an inpatient.  During pharmacist review of discharge orders, aspirin was not 
ordered.  New discharge order for aspirin was obtained. 
Dose too high: Dose too high Patient with atrial fibrillation was taking a lower dose of an anticoagulant 
(warfarin) in the hospital than what was being taken prior to admission.  
Discharge orders were written to resume home dose and start an interacting 
antibiotic that increases bleeding risk.  Based on inpatient dosing patterns 
and labs, discharge anticoagulant dose was lowered. 
Different drug needed: Dosage form 
inappropriate 
Patient with COPD had a discharge order for an albuterol inhaler.  During 
medication education, the pharmacist discovered the patient was using the 
inhaler by the incorrect route (intranasally instead of inhaled through the 
mouth) and was unable to manipulate the inhaler through the correct route.  
Discharge order was changed from an inhaler to nebules.   
Adverse drug reaction: Unsafe drug 
for patient 
Patient with CHF and chronic pain was taking a nonsteroidal anti-
inflammatory drug which was contributing to CHF symptoms.  Pain 
medication changed to acetaminophen to avoid exacerbation of symptoms. 
CHF = Congestive heart failure, COPD = Chronic obstructive pulmonary disease 
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Appendix A 
Pharmacist Discharge Education Script 
 
Acknowledge: “Good morning / afternoon / evening  ____________.” (see KBC Adult Patient Profile in FCIS under Documents to 
determine how patient prefers to be addressed) 
 
Introduce: “My name is ___________ and I am one of the hospital pharmacists and I’m here to talk to you about your medications.”  
 
Duration: “If it is ok with you, I’d like to take the next 5-10 minutes to go over the medications your doctor is sending you home on 
today.” 
 
Explanation: Using the discharge medication list, highlight the new, changed or discontinued medications.  State the name of the 
medication, what it’s treating, and any pertinent information (side effects, special instructions, etc.).  Ask the patient if he/she has 
any questions. 
Tell the patient that a scheduler will be calling them sometime within the next week to set-up a time to talk to another pharmacist.  
This pharmacist will help answer any questions the patient may have and will make sure that the patient’s medications are working 
well (helping him/her meet his/her goals of therapy), are safe for him/her to take, and that they fit with his/her lifestyle.  This 
specialized pharmacist can meet with the patient over the phone or in the clinic, whichever the patient/family prefers.  There is no 
charge for this service. 
 
Thank you: “Thank you for your time.  It was a pleasure to meet you __________.” 
 
 
Appendix B 
Pharmacy Discharge Medication Consult 
CONCERNS/RECOMMENDATIONS SHARED WITH INPATIENT PROVIDER: 
*** 
EDUCATION:  
Patient was informed to STOP taking the following HOME medications:   
*** 
Patient was informed to start taking the following NEW/CHANGED medications:  
*** 
Patient was educated on the following for each discharge medication: 
Rationale for therapy 
Duration of treatment 
Dosing and or monitoring drug levels 
Common side effects 
Importance of compliance 
Drug/food interactions 
Missed doses 
Self monitoring parameters 
OUTCOMES: 
Patient verbalized understanding 
Patient unable to express complete understanding 
Patient's family member verbalized understanding 
Unable to complete education due to *** 
IMPORTANT FOLLOW UP NOTES: 
*** 
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CHF = Congestive heart failure, COPD = Chronic obstructive pulmonary disease, MTM = Medication Therapy Management 
Note: Plex, FCIS, Assurance, and Epic are software systems outlined in Footnotes 
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Figure 2. Types of Drug Therapy Problems Found in Intervention Group 
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Figure 3. 30-Day All-Cause Readmission Rates for Intervention and Comparison Groups 
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